NCT04565665View on ClinicalTrials.gov

Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

July 29, 2020

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
COVID-19 InfectionCOVID-19-Associated Acute Respiratory Distress SyndromeHematopoietic and Lymphoid Cell NeoplasmMalignant Solid NeoplasmSymptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
OTHER

Best Practice

Receive standard of care

BIOLOGICAL

Mesenchymal Stem Cell

Given IV

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER